Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues
The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe.
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
CVS Weight Management program members achieved 15% average weight loss, with 92% satisfaction and 26% lower GLP-1 medication costs for participating clients.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 11.2%. This drawdown was much worse than the S&P 500’s 1.1% decline.
Elanco has gotten torched over the last six months - since September 2024, its stock price has dropped 28.5% to $10.39 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQSUPN).
Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results comparable to adults at 52 weeks.
